Intraperitoneal injection of thalidomide attenuates bone cancer pain and decreases spinal tumor necrosis factor-α expression in a mouse model

Molecular Pain

Volumn 6, Issue , 2010, Pages

  Gu, Xiaoping ^a   Zheng, Yaguo ^a   Ren, Bingxu ^a   Zhang, Rui ^a   Mei, Fengmei ^a   Zhang, Juan ^a   Ma, Zhengliang ^a  

^a MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA;

ALLODYNIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE CANCER; CANCER PAIN; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG MECHANISM; HYPERALGESIA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; ANIMAL; ANIMAL BEHAVIOR; BONE TUMOR; DISEASE MODEL; DRUG EFFECT; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; METABOLISM; PAIN; PATHOLOGY; SPINAL CORD; TIME; TUMOR CELL LINE;

ANIMALS; BEHAVIOR, ANIMAL; BONE NEOPLASMS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; INJECTIONS, INTRAPERITONEAL; MALE; MICE; PAIN; SPINAL CORD; THALIDOMIDE; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77957267232     PISSN: 17448069     EISSN: None     Source Type: Journal    
DOI: 10.1186/1744-8069-6-64     Document Type: Article

References (41)

1. Goblirsch MJ, Zwolak PP, Clohisy DR. Biology of bone cancer pain. Clin Cancer Res 2006, 12:6231s-6235s. 10.1158/1078-0432.CCR-06-0682, 17062706.
2. Clohisy DR, Mantyh PW. Bone cancer pain. Clin Orthop Relat Res 2003, S279-288. 10.1097/01.blo.0000093059.96273.56, 14600620.
3. Luger NM, Mach DB, Sevcik MA, Mantyh PW. Bone cancer pain: from model to mechanism to therapy. J Pain Symptom Manage 2005, 29:S32-46. 10.1016/j.jpainsymman.2005.01.008, 15907645.
4. Mercadante S. Malignant bone pain: pathophysiology and treatment. Pain 1997, 69:1-18. 10.1016/S0304-3959(96)03267-8, 9060007.
5. Colvin L, Fallon M. Challenges in cancer pain management--bone pain. Eur J Cancer 2008, 44:1083-1090. 10.1016/j.ejca.2008.03.001, 18439817.
6. Mercadante S, Fulfaro F. Management of painful bone metastases. Curr Opin Oncol 2007, 19:308-314. 10.1097/CCO.0b013e3281214400, 17545792.
7. Moreira AL, Wang J, Sarno EN, Kaplan G. Thalidomide protects mice against LPS-induced shock. Braz J Med Biol Res 1997, 30:1199-1207.
8. Moreira AL, Sampaio EP, Zmuidzinas A, Frindt P, Smith KA, Kaplan G. Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J Exp Med 1993, 177:1675-1680. 10.1084/jem.177.6.1675, 2191046, 8496685.
9. Sommer C, Marziniak M, Myers RR. The effect of thalidomide treatment on vascular pathology and hyperalgesia caused by chronic constriction injury of rat nerve. Pain 1998, 74:83-91. 10.1016/S0304-3959(97)00154-1, 9514564.
10. George A, Marziniak M, Schafers M, Toyka KV, Sommer C. Thalidomide treatment in chronic constrictive neuropathy decreases endoneurial tumor necrosis factor-alpha, increases interleukin-10 and has long-term effects on spinal cord dorsal horn met-enkephalin. Pain 2000, 88:267-275. 10.1016/S0304-3959(00)00333-X, 11068114.
11. Ribeiro RA, Vale ML, Ferreira SH, Cunha FQ. Analgesic effect of thalidomide on inflammatory pain. Eur J Pharmacol 2000, 391:97-103. 10.1016/S0014-2999(99)00918-8, 10720640.
12. Seadi Pereira PJ, Noronha Dornelles F, Santiago Santos D, Batista Calixto J, Bueno Morrone F, Campos MM. Nociceptive and inflammatory responses induced by formalin in the orofacial region of rats: effect of anti-TNFalpha strategies. Int Immunopharmacol 2009, 9:80-85. 10.1016/j.intimp.2008.10.001, 18957334.
13. Cata JP, Weng HR, Dougherty PM. The effects of thalidomide and minocycline on taxol-induced hyperalgesia in rats. Brain Res 2008, 1229:100-110. 10.1016/j.brainres.2008.07.001, 2577234, 18652810.
14. Schwei MJ, Honore P, Rogers SD, Salak-Johnson JL, Finke MP, Ramnaraine ML, Clohisy DR, Mantyh PW. Neurochemical and cellular reorganization of the spinal cord in a murine model of bone cancer pain. J Neurosci 1999, 19:10886-10897.
15. Bao L, Zhu Y, Elhassan AM, Wu Q, Xiao B, Zhu J, Lindgren JU. Adjuvant-induced arthritis: IL-1 beta, IL-6 and TNF-alpha are up-regulated in the spinal cord. Neuroreport 2001, 12:3905-3908. 10.1097/00001756-200112210-00010, 11742208.
16. Xu JT, Xin WJ, Zang Y, Wu CY, Liu XG. The role of tumor necrosis factor-alpha in the neuropathic pain induced by Lumbar 5 ventral root transection in rat. Pain 2006, 123:306-321. 10.1016/j.pain.2006.03.011, 16675114.
17. Reeve AJ, Patel S, Fox A, Walker K, Urban L. Intrathecally administered endotoxin or cytokines produce allodynia, hyperalgesia and changes in spinal cord neuronal responses to nociceptive stimuli in the rat. Eur J Pain 2000, 4:247-257. 10.1053/eujp.2000.0177, 10985868.
18. Youn DH, Wang H, Jeong SJ. Exogenous tumor necrosis factor-alpha rapidly alters synaptic and sensory transmission in the adult rat spinal cord dorsal horn. J Neurosci Res 2008, 86:2867-2875. 10.1002/jnr.21726, 18543334.
19. DeLeo JA, Rutkowski MD, Stalder AK, Campbell IL. Transgenic expression of TNF by astrocytes increases mechanical allodynia in a mouse neuropathy model. Neuroreport 2000, 11:599-602. 10.1097/00001756-200002280-00033, 10718321.
20. Boettger MK, Weber K, Grossmann D, Gajda M, Bauer R, Bar KJ, Schulz S, Voss A, Geis C, Brauer R, Schaible HG. Spinal TNF-alpha neutralization reduces peripheral inflammation and hyperalgesia and suppresses autonomic responses in experimental arthritis. Arthritis Rheum 2010, 62:1308-18.
21. Schafers M, Svensson CI, Sommer C, Sorkin LS. Tumor necrosis factor-alpha induces mechanical allodynia after spinal nerve ligation by activation of p38 MAPK in primary sensory neurons. J Neurosci 2003, 23:2517-2521.
22. Wacnik PW, Eikmeier LJ, Simone DA, Wilcox GL, Beitz AJ. Nociceptive characteristics of tumor necrosis factor-alpha in naive and tumor-bearing mice. Neuroscience 2005, 132:479-491. 10.1016/j.neuroscience.2004.12.035, 15802198.
23. Constantin CE, Mair N, Sailer CA, Andratsch M, Xu ZZ, Blumer MJ, Scherbakov N, Davis JB, Bluethmann H, Ji RR, Kress M. Endogenous tumor necrosis factor alpha (TNFalpha) requires TNF receptor type 2 to generate heat hyperalgesia in a mouse cancer model. J Neurosci 2008, 28:5072-5081. 10.1523/JNEUROSCI.4476-07.2008, 18463260.
24. Geis C, Graulich M, Wissmann A, Hagenacker T, Thomale J, Sommer C, Schafers M. Evoked Pain Behavior and Spinal Glia Activation is Dependent on Tumor Necrosis Factor Receptor 1 And 2 in a Mouse Model of Bone Cancer Pain. Neuroscience 2010, 169:463-474. 10.1016/j.neuroscience.2010.04.022, 20417692.
25. Pederson L, Winding B, Foged NT, Spelsberg TC, Oursler MJ. Identification of breast cancer cell line-derived paracrine factors that stimulate osteoclast activity. Cancer Res 1999, 59:5849-5855.
26. Tobinick EL. Targeted etanercept for treatment-refractory pain due to bone metastasis: two case reports. Clin Ther 2003, 25:2279-2288. 10.1016/S0149-2918(03)80219-9, 14512134.
27. Vale ML, Cunha FQ, Brito GA, Benevides VM, Ferreira SH, Poole S, Ribeiro RA. Anti-nociceptive effect of thalidomide on zymosan-induced experimental articular incapacitation. Eur J Pharmacol 2006, 536:309-317. 10.1016/j.ejphar.2006.02.051, 16597438.
28. Mika J, Osikowicz M, Makuch W, Przewlocka B. Minocycline and pentoxifylline attenuate allodynia and hyperalgesia and potentiate the effects of morphine in rat and mouse models of neuropathic pain. Eur J Pharmacol 2007, 560:142-149. 10.1016/j.ejphar.2007.01.013, 17307159.
29. Marchand F, Tsantoulas C, Singh D, Grist J, Clark AK, Bradbury EJ, McMahon SB. Effects of Etanercept and Minocycline in a rat model of spinal cord injury. Eur J Pain 2009, 13:673-681. 10.1016/j.ejpain.2008.08.001, 18849175.
30. Leung L, Cahill CM. TNF-alpha and neuropathic pain--a review. J Neuroinflammation 7:27. 10.1186/1742-2094-7-27, 2861665, 20398373.
31. Gu X, Zhang J, Ma Z, Wang J, Zhou X, Jin Y, Xia X, Gao Q, Mei F. The role of N-methyl-d-aspartate receptor subunit NR2B in spinal cord in cancer pain. Eur J Pain 2010, 14:496-502. 10.1016/j.ejpain.2009.09.001, 19815434.
32. Guo X, Zhou X, Zheng Y, Zhang J, Wang J, Ma Z. Involvement of the spinal NMDA receptor/PKCgamma signaling pathway in the development of bone cancer pain. Brain Res 2010, 1335:83-90. 10.1016/j.brainres.2010.03.083, 20362561.
33. Baamonde A, Curto-Reyes V, Juarez L, Meana A, Hidalgo A, Menendez L. Antihyperalgesic effects induced by the IL-1 receptor antagonist anakinra and increased IL-1beta levels in inflamed and osteosarcoma-bearing mice. Life Sci 2007, 81:673-682. 10.1016/j.lfs.2007.07.003, 17692876.
34. Medhurst SJ, Walker K, Bowes M, Kidd BL, Glatt M, Muller M, Hattenberger M, Vaxelaire J, O'Reilly T, Wotherspoon G, et al. A rat model of bone cancer pain. Pain 2002, 96:129-140. 10.1016/S0304-3959(01)00437-7, 11932069.
35. Zhang RX, Liu B, Wang L, Ren K, Qiao JT, Berman BM, Lao L. Spinal glial activation in a new rat model of bone cancer pain produced by prostate cancer cell inoculation of the tibia. Pain 2005, 118:125-136. 10.1016/j.pain.2005.08.001, 16154703.
36. Milligan ED, Watkins LR. Pathological and protective roles of glia in chronic pain. Nat Rev Neurosci 2009, 10:23-36. 10.1038/nrn2533, 2752436, 19096368.
37. De Sanctis JB, Mijares M, Suarez A, Compagnone R, Garmendia J, Moreno D, Salazar-Bookaman M. Pharmacological Properties of Thalidomide and Its Analogues. Recent Pat Inflamm Allergy Drug Discov 2010, 4:144-148. 10.2174/187221310791163026, 20307255.
38. Lee CJ, Kim KW, Lee HM, Nahm FS, Lim YJ, Park JH, Kim CS. The effect of thalidomide on spinal cord ischemia/reperfusion injury in a rabbit model. Spinal Cord 2007, 45:149-157. 10.1038/sj.sc.3101931, 16568139.
39. Zimmermann M. Ethical guidelines for investigations of experimental pain in conscious animals. Pain 1983, 16:109-110. 10.1016/0304-3959(83)90201-4, 6877845.
40. Tal M, Bennett GJ. Extra-territorial pain in rats with a peripheral mononeuropathy: mechano-hyperalgesia and mechano-allodynia in the territory of an uninjured nerve. Pain 1994, 57:375-382. 10.1016/0304-3959(94)90013-2, 7936715.
41. Hargreaves K, Dubner R, Brown F, Flores C, Joris J. A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia. Pain 1988, 32:77-88. 10.1016/0304-3959(88)90026-7, 3340425.